Ventura cofounded ADSCC in 2018 and was the general manager before becoming CEO in 2022. In May 2024, ADSCC received accreditation from the Foundation for the Accreditation of Cellular Therapy (FACT) for its cellular therapy program. ADSCC is one of two centers in the Middle East to meet FACT’s standards. In January 2024, ADSCC announced a joint research agreement with Kyoto University’s Center for iPS Cell Research and Application and Rege Nephro, a Japan-based biotech company. Ventura is also an adjunct professor at the United Arab Emirates University.